Novo Nordisk A/S Press Releases

Get NVO Alerts
*Delayed - data as of Aug. 27, 2014 10:45 ET  -  Find a broker to begin trading NVO now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    NVO Real Time
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Filtered By
Ordered By

Novo Nordisk Kicks Off HeroPathâ„¢ Life Coach Program for Teens and Young Adults With Hemophilia
8/25/2014 9:00:00 AM - PR Newswire

FDA Approves NovoSeven® RT for the Treatment of Glanzmann's Thrombasthenia (GT) With Refractoriness
7/7/2014 1:32:00 PM - PR Newswire

Novo Nordisk and NBA Legend Dominique Wilkins Spotlight Full-Court Approach to Type 2 Diabetes Management
6/25/2014 8:00:00 AM - PR Newswire

Phase 3a Liraglutide 3 mg Trial Demonstrated Significant Weight Loss and Improved Cardiovascular Risk Factors in Adults With Obesity and Type 2 Diabetes Compared With Placebo
6/21/2014 2:00:00 PM - PR Newswire

New Phase 3a Liraglutide 3 mg Data Showed Positive Impact on Cardiovascular Risk Markers and Fewer People Progressing to Pre-Diabetes Compared With Placebo in Adults With Obesity
6/21/2014 2:00:00 PM - PR Newswire

Novo Nordisk Announces U.S. Launch of New Insulin Device Levemir® FlexTouch®
6/19/2014 9:00:00 AM - PR Newswire

New Phase 3 Study Shows Efficacy and Safety of Victoza® (Liraglutide [rDNA origin] Injection) for the Treatment of Type 2 Diabetes in Adults with Moderate Renal Impairment
6/14/2014 1:00:00 PM - PR Newswire

New One-year Data of IDegLira Shows Glucose-lowering Effect was Maintained for People with Type 2 Diabetes
6/14/2014 11:45:00 AM - PR Newswire

Phase 3a Data Showed Liraglutide 3 mg Demonstrated Significantly Greater Weight Loss Compared to Placebo in Adults With Obesity and Type 2 Diabetes
6/14/2014 11:30:00 AM - PR Newswire

Health Care Sector Equities Coverage -- Research on Johnson and Johnson, Medicines Co., Merck, and Novo Nordisk
6/13/2014 7:40:00 AM - PR Newswire

Novo Nordisk Honored with 2014 New Good Neighbor Award by New Jersey Business & Industry Association
6/6/2014 9:00:00 AM - PR Newswire